Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Shlofmitz

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2024
Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trialUsman Baber, Davide Cao, Timothy Collier, et al.
JACC. Cardiovascular Interventions|July 9, 2021
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCIDominick J Angiolillo, Davide Cao, Usman Baber, et al.
European Heart Journal|August 23, 2021
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKDGiulio G Stefanini, Carlo Briguori, Davide Cao, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 24, 2022
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKDPayam Dehghani, Davide Cao, Usman Baber, et al.
Journal of the American College of Cardiology|August 17, 2023
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary InterventionsGuiomar Mendieta, Shamir Mehta, Usman Baber, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 18, 2022
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG studyGennaro Sardella, Frans J Beerkens, George Dangas, et al.
JACC. Cardiovascular Interventions|October 25, 2023
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary InterventionDominick J Angiolillo, Davide Cao, Samantha Sartori, et al.
JACC. Cardiovascular Interventions|January 16, 2022
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT SubstudyMauro Chiarito, Usman Baber, Davide Cao, et al.
The New England Journal of Medicine|September 27, 2019
Ticagrelor with or without Aspirin in High-Risk Patients after PCIRoxana Mehran, Usman Baber, Samin K Sharma, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 9, 2021
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT studyGeorge Dangas, Usman Baber, Samin Sharma, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2024
Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trialUsman Baber, Davide Cao, Timothy Collier, et al.
JACC. Cardiovascular Interventions|July 9, 2021
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCIDominick J Angiolillo, Davide Cao, Usman Baber, et al.
European Heart Journal|August 23, 2021
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKDGiulio G Stefanini, Carlo Briguori, Davide Cao, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 24, 2022
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKDPayam Dehghani, Davide Cao, Usman Baber, et al.
Journal of the American College of Cardiology|August 17, 2023
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary InterventionsGuiomar Mendieta, Shamir Mehta, Usman Baber, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 18, 2022
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG studyGennaro Sardella, Frans J Beerkens, George Dangas, et al.
JACC. Cardiovascular Interventions|October 25, 2023
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary InterventionDominick J Angiolillo, Davide Cao, Samantha Sartori, et al.
JACC. Cardiovascular Interventions|January 16, 2022
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT SubstudyMauro Chiarito, Usman Baber, Davide Cao, et al.
The New England Journal of Medicine|September 27, 2019
Ticagrelor with or without Aspirin in High-Risk Patients after PCIRoxana Mehran, Usman Baber, Samin K Sharma, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 9, 2021
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT studyGeorge Dangas, Usman Baber, Samin Sharma, et al.
Pageof 8